|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's range||0.0042 - 0.0060|
|52-week range||0.0034 - 0.0815|
|Beta (5Y monthly)||3.94|
|PE ratio (TTM)||N/A|
|Earnings date||20 Jan 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has an extensive intellectual property portfolio consisting of granted patents, published applications and pending applications. Regen, and its wholly-owned subsidiary KCL Therapeutics, Inc., own the following patent portfolio:
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced a program to accelerate the clinical development of its NR2F6 therapies. The Company intends to combine modified mRNA technology with Regen's existing siRNA ( small interfering RNA) intellectual property targeting the NR2F6 nuclear receptor which has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator.
Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP) is embarking on a development program to commercialize its modified mRNA anti-cancer vaccine targeting the Survivin protein. In the first phase of the development program, Regen will design and have experiments carried out that will form the initial series of pre-clinical studies required as part of an FDA IND submission.